Yahoo Web Search

  1. Bristol-Myers Squibb Company BMY suffered a setback as a late-stage study evaluating its blockbuster immuno-oncology drug Opdivo for the treatment of malignant brain tumor failed to meet its ...

  2. Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion

    Zacks via Yahoo FinanceAug 28 14:15 PM

    Bristol-Myers Squibb Company BMY announced that the European Medicines Agency ("EMA") has approved the label expansion of Empliciti in combination with Celgene’s CELG Pomalyst (pomalidomide) ...

  3. Stocks recently featured in the blog include: Allergan AGN, Merck MRK and Roche RHHBY, J&J JNJ and Bristol-Myers BMY. This week, Allergan settled with two counties of Ohio for $5 million ...

  4. Roche Holding AG RHHBY recently announced that the European Commission (EC) has approved and granted marketing authorization to two indications of its immuno-oncology drug, Tecentriq (atezolizumab ...

  5. Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

    Zacks via Yahoo FinanceSep 09 20:39 PM

    Eli Lilly and Company's LLY oral RET inhibitor selpercatinib (LOXO-292) demonstrated a 68% objective response rate (ORR) or shrinkage in tumor size in heavily pretreated patients with RET fusion-positive ...

  6. Buy 5 Top Dow Stocks to Gain From Index's Rally

    Zacks via Yahoo FinanceSep 10 11:11 AM

    In line with the broader market, the Dow 30 Index ---- popularly known as the blue-chip index of Wall Street ---- gained in previous four successive trading sessions, posting its longest winning ...

  7. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co ...

  8. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co ...

  9. Novartis AG NVS announced that the FDA has granted a Breakthrough Therapy designation to its MET inhibitor capmatinib (INC280) for the first-line treatment of patients with metastatic MET exon14 ...

  10. So far this year, GlaxoSmithKline plc’s GSK shares have outperformed the industry. Trelegy Ellipta, which provides three medicines in a single inhaler to treat COPD and Juluca (dolutegravir ...

  1. Ads
    related to MERCK & CO., INC